Overview

A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty

Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label dose-escalating study to evaluate the tolerability and systemic exposure of MDT-10013 in men and women at least 18 years of age who are undergoing primary unilateral TKA.
Phase:
Phase 2
Details
Lead Sponsor:
Medtronic Spinal and Biologics